Patrys Ltd (ASX: PAB) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
Patrys Ltd Chart and Price Data
Fundamentals Data provided by Morningstar.
Data provided by Morningstar.
Market Cap
$17.13 million
P/E Ratio
N/A
Dividend Yield
0.00%
Shares Outstanding
535.37 million
Earnings per share
-0.021
Dividend per share
N/A
Year To Date Return
14.29%
Earnings Yield
N/A
Franking
-
Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
Patrys Ltd (ASX: PAB)
Latest News
Healthcare Shares
Here's why the Patrys (ASX:PAB) share price is tumbling 16% today
Share Market News
Here's why the Patrys (ASX: PAB) share price is climbing 13% today
Ask a Fund Manager
Why we avoid mining and biotech ASX shares: fund manager
PAB ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
| Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
|---|---|---|---|---|---|
| YesNo |
About Patrys Ltd
Patrys Ltd is a biopharmaceutical company focused on developing novel antibody-based therapies prominently for cancer and related inflammatory diseases. Its core technology platform involves antibodies that penetrate cell nuclei and inhibit cancer cell DNA repair mechanisms. The company advances therapeutic candidates from its antibody platforms, including ones licensed from Yale University, with ongoing preclinical and clinical development activities. Patrys generates revenue through licensing agreements and collaborations linked to its antibody technologies. Its operations and development efforts span Australia and the United States.
PAB Share Price History Data provided by Morningstar.
| Date | Close | Change | % Change | Volume | Open | High | Low |
|---|---|---|---|---|---|---|---|
| 12 Mar 2026 | $0.03 | $0.00 | 0.00% | 142,789 | $0.03 | $0.03 | $0.03 |
| 11 Mar 2026 | $0.03 | $0.00 | 0.00% | 247,130 | $0.03 | $0.03 | $0.03 |
| 10 Mar 2026 | $0.03 | $0.00 | 0.00% | 912,936 | $0.03 | $0.04 | $0.03 |
| 09 Mar 2026 | $0.03 | $0.00 | 0.00% | 203,999 | $0.04 | $0.04 | $0.03 |
| 06 Mar 2026 | $0.04 | $0.00 | 0.00% | 461,797 | $0.04 | $0.04 | $0.03 |
| 05 Mar 2026 | $0.04 | $0.00 | 0.00% | 144,682 | $0.04 | $0.04 | $0.04 |
| 04 Mar 2026 | $0.04 | $0.00 | 0.00% | 461,991 | $0.04 | $0.04 | $0.04 |
| 03 Mar 2026 | $0.04 | $0.00 | 0.00% | 871,437 | $0.04 | $0.04 | $0.04 |
| 02 Mar 2026 | $0.04 | $0.00 | 0.00% | 429,144 | $0.04 | $0.04 | $0.04 |
| 27 Feb 2026 | $0.04 | $0.00 | 0.00% | 1,023,432 | $0.04 | $0.04 | $0.04 |
| 26 Feb 2026 | $0.04 | $0.00 | 0.00% | 2,160,098 | $0.04 | $0.04 | $0.04 |
| 25 Feb 2026 | $0.04 | $0.01 | 28.57% | 8,424,930 | $0.04 | $0.04 | $0.04 |
| 24 Feb 2026 | $0.04 | $0.00 | 0.00% | 240,631 | $0.04 | $0.04 | $0.04 |
| 23 Feb 2026 | $0.03 | $0.00 | 0.00% | 661,976 | $0.04 | $0.04 | $0.03 |
| 20 Feb 2026 | $0.04 | $0.00 | 0.00% | 228,208 | $0.03 | $0.04 | $0.03 |
| 19 Feb 2026 | $0.03 | $0.00 | 0.00% | 30,000 | $0.03 | $0.03 | $0.03 |
| 18 Feb 2026 | $0.03 | $0.00 | 0.00% | 340,387 | $0.03 | $0.03 | $0.03 |
| 17 Feb 2026 | $0.03 | $0.00 | 0.00% | 120,000 | $0.03 | $0.03 | $0.03 |
| 16 Feb 2026 | $0.03 | $0.00 | 0.00% | 848,779 | $0.04 | $0.04 | $0.03 |
| 13 Feb 2026 | $0.04 | $0.00 | 0.00% | 523,071 | $0.04 | $0.04 | $0.04 |
| 12 Feb 2026 | $0.04 | $0.00 | 0.00% | 2,130,731 | $0.04 | $0.04 | $0.04 |
| 11 Feb 2026 | $0.04 | $0.00 | 0.00% | 878,299 | $0.04 | $0.04 | $0.04 |
| 10 Feb 2026 | $0.04 | $0.00 | 0.00% | 278,967 | $0.03 | $0.04 | $0.03 |
Director Transactions Data provided by Morningstar.
| Date | Director | Type | Amount | Value | Notes |
|---|---|---|---|---|---|
| 10 Feb 2026 | Brian Leedman | Issued | 5,000,000 | $175,000 |
Issue of options.
|
| 10 Feb 2026 | Brian Leedman | Transfer | 2,000,000 | $30,000 |
Off-market transfer.
|
| 22 Oct 2025 | James Campbell | Issued | 10,701,795 | $160,526 |
Issue of securities. Deemed issue price
|
| 22 Oct 2025 | Anton Uvarov | Issued | 3,333,333 | $50,000 |
Placement.
|
| 22 Oct 2025 | Anton Uvarov | Issued | 1,666,666 | $49,999 |
Placement.
|
| 22 Oct 2025 | Anton Uvarov | Issued | 6,666,666 | $199,999 |
Rights issue.
|
| 22 Oct 2025 | Peter Christie | Issued | 833,333 | $24,999 |
Rights issue.
|
| 30 Sep 2025 | James Campbell | Expiry | 23,389,950 | $46,779 |
Options expired.
|
| 04 Sep 2025 | Anton Uvarov | Issued | 200,000,000 | $200,000 |
Rights issue.
|
| 04 Sep 2025 | Anton Uvarov | Issued | 50,000,000 | $50,000 |
As advised by the company.
|
| 04 Sep 2025 | Peter Christie | Issued | 6,250,000 | $6,250 |
Rights issue.
|
| 04 Sep 2025 | Peter Christie | Issued | 25,000,000 | $25,000 |
Rights issue.
|
| 28 Aug 2025 | James Campbell | Issued | 16,296,678 | $32,593 |
Rights issue.
|
| 28 Aug 2025 | James Campbell | Issued | 1,408,125 | $2,816 |
Rights issue.
|
| 01 Jul 2025 | James Campbell | Expiry | 1,610,050 | $1,610 |
Options expired.
|
Directors & Management Data provided by Morningstar.
| Name | Title | Start Date | Profile |
|---|---|---|---|
| Mr Peter James Christie | Non-Executive ChairmanNon-Executive Director | Jun 2025 |
Mr Christie has over 25 years of experience in public accounting. He has served on the boards of several public companies in the resource sector since 2006 and has developed interests in hospitality and property development. He has experience in the medical industry, having previously served as Chairman of Safety Medical Products Limited. He also has a background in finance, corporate governance, and community leadership positions.
|
| Mr Brian Willoughby Leedman | Non-Executive Director | Nov 2025 |
Mr Leedman is a biotechnology executive and company director with more than 20 years of experience in corporate strategy, investor relations, and capital markets within the life sciences sector. He is the founder and former director of ResApp Health Ltd, which was acquired by Pfizer Inc. in 2022, and has held board roles across a range of ASX-listed biotechnology companies, including Neuroscientific Biopharmaceuticals, Neurotech International, Alcidion Corporation, Oncosil and others. Mr Leedman is currently a Non-Executive Chairman of Blinklab Ltd and has experience guiding emerging biomedical companies from early research through to clinical development and commercialisation.
|
| Dr Anton Uvarov | Non-Executive Director | Jun 2025 |
Dr Uvarov has experience in the healthcare sector, with a particular focus on neuroscience. He began his career in biotechnology investment as an equities analyst at Citigroup and has since co-founded and served as a director of several ASXlisted companies.
|
| Ms Leanne Kite | Non-Executive Director | Jan 2026 |
Ms Kite is a finance, governance, and investor relations executive with over 20 years of experience in the biotech, resources and energy sectors. A co-founder of Reliis, her professional background includes 13 years in senior finance, strategy and planning roles at Woodside Energy. She currently leads Investor Relations for an ASX 200 mining company and serves as a Non-Executive Director of Mosaic Community Care, where she chairs the Finance and Investment Committee and the Remuneration and Nominations Committee.
|
| Mr Dino Cercarelli | Non-Executive Director | Jan 2026 |
Mr Cercarelli is a healthcare and clinical research operations executive with over two decades of experience. His professional background includes eight years at St John of God Health Care (SJGHC), where he led research and clinical trial operations. He is the current Chief Operating Officer of the Australian Clinical Trials Alliance (ACTA), the national peak body for clinical trials and clinical quality registries. He also serves on the CT.IQ Executive and Steering Committees and the PARTNER Network Advisory Group.
|
| Mr Johnathon Busing | Joint Company Secretary | Nov 2025 |
-
|
| Mr Kieran Witt | Joint Company Secretary | Nov 2025 |
-
|
| Johnathon Busing | Joint Company Secretary |
-
|
|
| Kieran Witt | Joint Company Secretary |
-
|
Top Shareholders Data provided by Morningstar.
| Name | Shares | Capital |
|---|---|---|
| Mr Anton Uvarov | 250,000,000 | 5.45% |
| Mr Mladen Marusic | 133,828,078 | 2.92% |
| Warragoon Investments Pty Ltd | 130,937,500 | 2.86% |
| Hevel Pty Ltd <Colourful A/C> | 121,699,223 | 2.66% |
| Citicorp Nominees Pty Limited | 113,152,317 | 2.47% |
| Cosann Pty Ltd | 106,356,036 | 2.32% |
| Mr Dennis Brian Jones + Mrs Jennifer Anne Jones <Jones Super Fund A/C> | 100,000,000 | 2.18% |
| Stork Holdings 2010 Ltd | 98,773,814 | 2.15% |
| Dr Dax Marcus Calder | 89,000,000 | 1.94% |
| Mr Robert Philip Grant | 87,510,643 | 1.91% |
| Ratdog Pty Ltd | 87,500,000 | 1.91% |
| Bt Global Holdings Pty Ltd <Bt Unit A/C> | 81,387,485 | 1.78% |
| Mr Paul Gregory Brown + Mrs Jessica Oriwia Brown <Brown Super Fund A/C> | 75,001,401 | 1.64% |
| Ascension Growth (Wa) Fund Pty Ltd | 73,437,500 | 1.60% |
| Mr Peter Darren Russell | 73,125,000 | 1.60% |
| Dax Calder Pty Ltd | 65,000,000 | 1.42% |
| Towns Corporation Pty Ltd <Pae Family A/C> | 61,447,812 | 1.34% |
| Bg Development Fund Pty Ltd <Bg Investment A/C> | 50,000,000 | 1.09% |
| Sabre Power Systems Pty Ltd | 46,146,250 | 1.01% |
| Wendake Pty Ltd <L'Heureux A/C> | 43,125,701 | 0.94% |